BAXTER INTL INC shareholders Q3 2023

BAXTER INTL INC's ticker is BAX and the CUSIP is 071813109. A total of 885 filers reported holding BAXTER INTL INC in Q3 2023. The put-call ratio across all filers is 0.40 and the average weighting 0.2%.

BAXTER INTL INC shareholders Q3 2023
NameSharesValueWeighting ↓
NEVILLE RODIE & SHAW INC 33,276$1,2560.11%
Ipswich Investment Management Co., Inc. 10,625$400,9880.11%
LBP AM SA 130,498$4,924,9950.11%
Community Financial Services Group, LLC 11,310$426,8390.11%
Norway Savings Bank 5,680$214,3630.11%
FIRST COMMUNITY TRUST NA 2,400$90,5760.10%
Manchester Capital Management LLC 18,629$703,0590.10%
Cedar Wealth Management, LLC 6,907$260,6700.10%
FIL Ltd 2,294,826$86,606,7330.10%
CALIFORNIA PUBLIC EMPLOYEES RETIREMENT SYSTEM 3,151,515$118,938,1760.10%
SevenBridge Financial Group, LLC 10,503$396,3830.10%
AMUSSEN HUNSAKER ASSOCIATES LLC 11,223$421,3110.10%
PRICE T ROWE ASSOCIATES INC /MD/ 17,159,292$647,5920.10%
SkyView Investment Advisors, LLC 6,150$2320.09%
BAKER TILLY WEALTH MANAGEMENT, LLC 15,025$567,0440.09%
Manning & Napier Group, LLC 196,004$7,397,1910.09%
Quantinno Capital Management LP 53,617$2,024,0000.09%
FRANKLIN RESOURCES INC 4,802,749$181,255,7480.09%
OSTRUM ASSET MANAGEMENT 26,347$994,3360.09%
FRG Family Wealth Advisors LLC 10,549$398,1190.09%
About BAXTER INTL INC

Baxter International Inc. is a global healthcare company that specializes in developing and manufacturing medical products and therapies. The company has a long history of innovation and has been at the forefront of developing life-saving treatments for patients around the world.

Baxter's product portfolio includes a wide range of medical devices, pharmaceuticals, and biotechnology products. The company's products are used in hospitals, clinics, and other healthcare settings to treat a variety of conditions, including hemophilia, immune disorders, kidney disease, and other chronic and acute medical conditions.

Baxter's commitment to innovation has helped the company maintain a strong position in the healthcare industry. The company invests heavily in research and development, and has a strong pipeline of new products in development.

Baxter's leadership team is also a key strength of the company. The CEO, José Almeida, has a strong track record of success in the healthcare industry, and has been instrumental in driving the company's growth and success.

Overall, Baxter International Inc. is a strong and innovative company that is well-positioned to continue delivering value to patients, healthcare providers, and investors alike. With a strong product portfolio, a commitment to innovation, and a talented leadership team, Baxter is a company that investors should keep an eye on in the years to come.

It's important to note that this information is for educational purposes only and has not been fact-checked. As with any investment, it's important to do your own research and consult with a financial advisor before making any investment decisions.

External links

This page lists BAXTER INTL INC's shareholders in Q3 2023. To view BAXTER INTL INC's shareholder history, click here.